Company profile: Mereo Biopharma
1.1 - Company Overview
Company description
- Provider of UK-based specialty biopharmaceutical development and funding of novel, specialist-focused products sourced from large pharmaceutical and biotechnology companies. Portfolio includes Setrusumab for osteogenesis imperfecta, Alvelestat for AATD-associated lung disease, Etigilimab for advanced solid tumors, Navixizumab for post-platinum ovarian cancer, and Leflutrozole for hormonal disorders.
Products and services
- Alvelestat: An oral inhibitor targeting neutrophil elastase for Alpha-1 Antitrypsin Deficiency-associated lung disease, aiming to protect the lungs by slowing damage
- Setrusumab: A monoclonal antibody for Osteogenesis Imperfecta that inhibits sclerostin to potentially reduce fractures and improve bone density
- Etigilimab: Investigational therapy for advanced or metastatic solid tumors, designed to enhance immune response against cancer
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Mereo Biopharma
AOP Orphan Pharmaceuticals
HQ: Austria
Website
- Description: Provider of medicines for orphan indications and complex diseases, engaging in their development, marketing, and distribution.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full AOP Orphan Pharmaceuticals company profile →
Pharming
HQ: The Netherlands
Website
- Description: Provider of protein replacement therapies and precision medicines, including Joenja (leniolisib), an oral, selective PI3Kδ inhibitor approved to treat activated phosphoinositide 3-kinase delta syndrome (APDS) in patients aged 12 and older.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Pharming company profile →
Palvella Therapeutics
HQ: United States
Website
- Description: Provider of therapies for abandoned patient populations.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Palvella Therapeutics company profile →
AveXis
HQ: United States
Website
- Description: Provider of gene therapies specializing in the development and commercialization for patients and families affected by rare and life-threatening neurological genetic diseases; doing business as Novartis Gene Therapies, Inc. following Novartis’s 2018 acquisition and 2020 renaming.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full AveXis company profile →
Longboard Pharmaceuticals
HQ: United States
Website
- Description: Provider of medicines with optimized pharmacology and pharmacokinetics for rare neurological diseases, with a proprietary pipeline including bexicaserin (LP352), an oral, centrally acting 5-HT2C receptor superagonist in development for treating seizures associated with Developmental and Epileptic Encephalopathies, and LP659, an oral S1P receptor modulator for rare neuroinflammatory conditions, plus Longboard Assist patient support services.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Longboard Pharmaceuticals company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Mereo Biopharma
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Mereo Biopharma
2.2 - Growth funds investing in similar companies to Mereo Biopharma
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Mereo Biopharma
4.2 - Public trading comparable groups for Mereo Biopharma
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →